Related Experiment Video
Updated: Sep 27, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Cetuximab in Patients with Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Alterations
Mina Nikanjam1, Shumei Kato1, Jacob J Adashek2
1Center for Personalized Cancer Therapy and Division of Hematology and Oncology, UC San Diego Moores Cancer Center, San Diego, USA.
Abstract:
Epidermal Growth Factor Receptor (EGFR) exon 20 insertion alterations represent 4%-10% of all EGFR mutations in Non-Small Cell Lung Cancer (NSCLC) and result in resistance to standard EGFR-directed therapies. EGFR exon 20 insertions restrict the size of the kinase pocket, prohibiting the entry of approved EGFR kinase inhibitor drugs. Structural In Silico modeling also predicts that EGFR exon 20 insertion anomalies increase attractive electrostatic dimerization, hence stabilizing the activating dimer configuration. EGFR antibodies such as cetuximab that interfere with dimerization may lead to responses. We identified three non-smoking patients with NSCLC and EGFR exon 20 insertions treated with cetuximab-based therapy. All three patients demonstrated clinical benefit. A 58-year-old woman achieved prolonged stable disease lasting 9 months, while a 76-year-old woman and 38-year-old man maintained a partial response with progression-free survivals of 13 months and 32 months, respectively. In conclusion, cetuximab merits further investigation as it appears to be an additional promising therapy for overcoming EGFR exon 20 insertion-related resistance.
Insights
Cetuximab shows promise for treating Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertions. This therapy offers clinical benefits, including prolonged stable disease and partial responses in patients resistant to standard treatments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Epidermal Growth Factor Receptor (EGFR) exon 20 insertions are found in 4%-10% of Non-Small Cell Lung Cancer (NSCLC) cases.
- These mutations confer resistance to existing EGFR-targeted therapies by altering the kinase pocket and promoting dimerization.
- EGFR antibodies may overcome resistance by interfering with receptor dimerization.
Purpose of the Study:
- To investigate the efficacy of cetuximab-based therapy in NSCLC patients with EGFR exon 20 insertion mutations.
- To evaluate clinical benefit and progression-free survival in this patient cohort.
Main Methods:
- Retrospective analysis of three non-smoking NSCLC patients with EGFR exon 20 insertions.
- Treatment with cetuximab-based therapy.
- Assessment of clinical benefit, including stable disease and partial response.
Main Results:
- All three patients demonstrated clinical benefit from cetuximab-based therapy.
- One patient achieved stable disease for 9 months.
- Two patients achieved partial responses with progression-free survival of 13 and 32 months.
Conclusions:
- Cetuximab demonstrates potential as a therapeutic option for NSCLC patients with EGFR exon 20 insertion mutations.
- Further investigation of cetuximab is warranted to overcome resistance to standard EGFR inhibitors.
- EGFR antibody therapy represents a promising avenue for managing this subset of NSCLC.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle